Glutaredoxin 2 is essential for AML survival through mitochondrial permeability transition pore regulation.

Saved in:
Bibliographic Details
Title: Glutaredoxin 2 is essential for AML survival through mitochondrial permeability transition pore regulation.
Authors: Ling T; Princess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada.; Department of Medical Biophysics, University of Toronto, Toronto, ON, Canada., O'Brien C; Princess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada.; Department of Medical Biophysics, University of Toronto, Toronto, ON, Canada., St-Germain JR; Princess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada., Rondeau V; Princess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada., Shi M; Princess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada., Berman JM; Princess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada., Cepa A; Division of Experimental Hematology and Cancer Biology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH.; Advanced Leukemia Therapies and Research Center, Cincinnati Children's Hospital, Cincinnati, OH.; Department of Pediatrics, University of Cincinnati, Cincinnati, OH., Saez Raez P; Division of Experimental Hematology and Cancer Biology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH.; Advanced Leukemia Therapies and Research Center, Cincinnati Children's Hospital, Cincinnati, OH.; Department of Cancer and Cell Biology, University of Cincinnati, Cincinnati, OH., Wunderlich M; Division of Experimental Hematology and Cancer Biology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH.; Advanced Leukemia Therapies and Research Center, Cincinnati Children's Hospital, Cincinnati, OH., Carter KM; Division of Experimental Hematology and Cancer Biology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH.; Advanced Leukemia Therapies and Research Center, Cincinnati Children's Hospital, Cincinnati, OH., Stillwell C; Division of Experimental Hematology and Cancer Biology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH.; Advanced Leukemia Therapies and Research Center, Cincinnati Children's Hospital, Cincinnati, OH., Sexton C; Division of Experimental Hematology and Cancer Biology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH.; Advanced Leukemia Therapies and Research Center, Cincinnati Children's Hospital, Cincinnati, OH., Culp-Hill R; Department of Biochemistry and Molecular Genetics, University of Colorado Anschutz Medical Campus, Aurora, CO., Reisz JA; Department of Biochemistry and Molecular Genetics, University of Colorado Anschutz Medical Campus, Aurora, CO., Adeel SA; Princess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada.; Department of Medical Biophysics, University of Toronto, Toronto, ON, Canada., Zeng AGX; Princess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada.; Department of Molecular Genetics, University of Toronto, Toronto, ON, Canada., Bansal S; Princess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada.; Department of Molecular Genetics, University of Toronto, Toronto, ON, Canada., Tsao E; Princess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada.; Department of Medical Biophysics, University of Toronto, Toronto, ON, Canada., Chen HT; Princess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada., Dick JE; Department of Molecular Genetics, University of Toronto, Toronto, ON, Canada., Minden MD; Princess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada., Arruda A; Princess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada., Amaya ML; Division of Hematology, Department of Medicine, University of Colorado Anschutz Medical Campus, Aurora, CO., Tikhonova AN; Princess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada.; Department of Medical Biophysics, University of Toronto, Toronto, ON, Canada.; Ontario Institute for Cancer Research, Toronto, ON, Canada., Hope KJ; Princess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada.; Department of Medical Biophysics, University of Toronto, Toronto, ON, Canada.; Ontario Institute for Cancer Research, Toronto, ON, Canada., D'Alessandro A; Department of Biochemistry and Molecular Genetics, University of Colorado Anschutz Medical Campus, Aurora, CO., Raught B; Princess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada.; Department of Medical Biophysics, University of Toronto, Toronto, ON, Canada., Jones CL; Princess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada.; Department of Medical Biophysics, University of Toronto, Toronto, ON, Canada.; Division of Experimental Hematology and Cancer Biology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH.; Advanced Leukemia Therapies and Research Center, Cincinnati Children's Hospital, Cincinnati, OH.; Department of Pediatrics, University of Cincinnati, Cincinnati, OH.; University of Cincinnati Cancer Center, Cincinnati, OH.
Source: Blood [Blood] 2026 Feb 19; Vol. 147 (8), pp. 863-876.
Publication Type: Journal Article
Journal Info: Publisher: Elsevier Country of Publication: United States NLM ID: 7603509 Publication Model: Print Cited Medium: Internet ISSN: 1528-0020 (Electronic) Linking ISSN: 00064971 NLM ISO Abbreviation: Blood Subsets: MEDLINE
Database: MEDLINE Ultimate
Description
ISSN:1528-0020
DOI:10.1182/blood.2025028933